Sign in to fuzzto save your conversations, follow your research and come back anytime.
Viyash Scientific
VIYASH
NSE
BSE
NSEBSESectorHealthcare
260.45
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Viyash Scientific scales revenue and profitability while managing rising operational costs and margin pressure.
EBITDA margin expands from 16.2% in Q1 FY26 to 21.6% in Q1 FY27, sustaining operational efficiency.
Gross profit margin slips from 61.1% in Q2 FY26 to 54.1% in Q1 FY27, showing pricing pressure.
Reported sales revenue grows from ₹4,240 Cr in Q2 FY26 to ₹9,464 Cr in Q1 FY27, confirming strong top-line expansion.
Operating expenses widen from ₹1,369 Cr in Q1 FY26 to ₹1,696 Cr in Q1 FY27, reflecting scaling overheads.
Customer audits rise from 34 in Q1 FY26 to 66 in Q1 FY27, reflecting growing client trust.
Material consumption costs deepen from ₹1,480 Cr in Q1 FY26 to ₹4,343 Cr in Q1 FY27, indicating higher production input costs.
R&D pipeline products jump from 16 in Q2 FY26 to 190 in Q1 FY27, signaling aggressive future growth.
Employee benefit expenses rise from ₹677 Cr in Q1 FY26 to ₹1,381 Cr in Q1 FY27, signaling workforce expansion costs.
Net debt to LTM EBITDA falls from 0.6x in Q1 FY26 to 0.1x in Q1 FY27, confirming a strong balance sheet.
API regulatory approvals fluctuate from 5 in Q1 FY26 to 3 in Q1 FY27, indicating uneven compliance pacing.